CSCI
vs
S&P 500
CSCI
S&P 500
Over the past 12 months, CSCI has underperformed S&P 500, delivering a return of -26% compared to the S&P 500's +15% growth.
Stocks Performance
CSCI vs S&P 500
Performance Gap
CSCI vs S&P 500
Performance By Year
CSCI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
COSCIENS Biopharma Inc
Glance View
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
